PharmaCyte Biotech Releases Proxy Statement Related to Special Shareholder Meeting
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Aug 27, 2019--
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today announced that its proxy statement related to the announced Special Shareholder Meeting on September 11, 2019, is available on PharmaCyte’s website at: https://ir.pharmacytebiotech.com/proxy.
The only opportunity to actively participate in the meeting is to attend it in person. However, the votes of shareholders of record can be cast using the proxy card that has already been sent out to each shareholder of record and to the broker/dealers of those shareholders who hold their shares in street name (with a broker/dealer).
If there is quorum present at the September 11 meeting, the meeting will take place as scheduled. If that occurs, PharmaCyte will be providing the results of the votes cast in favor of or in opposition to the three propositions on the proxy card. The proceedings of the Special Shareholder Meeting will not be taped or broadcast live. If a meeting does take place, PharmaCyte will be providing a brief summary in a press release stating what took place and what was discussed at the meeting.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. (PharmaCyte) is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box ®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment-related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box ® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte, including statements regarding the timing and commencement of our first Phase 2b clinical trial. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.
More information about PharmaCyte can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190827005286/en/
CONTACT: Dr. Gerald W. Crabtree
PharmaCyte Biotech, Inc.
Investor Relations Department
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: RESEARCH PHARMACEUTICAL ONCOLOGY GENETICS STEM CELLS SCIENCE CLINICAL TRIALS GENERAL HEALTH BIOTECHNOLOGY DIABETES PUBLIC RELATIONS/INVESTOR RELATIONS HEALTH COMMUNICATIONS
SOURCE: PharmaCyte Biotech, Inc.
Copyright Business Wire 2019.
PUB: 08/27/2019 09:20 AM/DISC: 08/27/2019 09:20 AM